AZD4635 + Durvalumab + Cabazitaxel
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Progressive Metastatic Castrate-Resistant Prostate Cancer
Conditions
Progressive Metastatic Castrate-Resistant Prostate Cancer
Trial Timeline
Aug 4, 2020 → Aug 8, 2022
NCT ID
NCT04495179About AZD4635 + Durvalumab + Cabazitaxel
AZD4635 + Durvalumab + Cabazitaxel is a phase 2 stage product being developed by AstraZeneca for Progressive Metastatic Castrate-Resistant Prostate Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT04495179. Target conditions include Progressive Metastatic Castrate-Resistant Prostate Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04495179 | Phase 2 | Completed |
Competing Products
20 competing products in Progressive Metastatic Castrate-Resistant Prostate Cancer